Skip to content
Open access

MX2 and IRF7 are Associated With Disease Activity and Renal Involvement in Systemic Lupus Erythematosus: An Exploratory Study

Jan 2026 · Journal of Immunological Research · Vol 2026 · 0 citations · 37 references
Medicine

TL;DR

This study identifies MX2 and IRF7 as candidate biomarkers associated with high systemic disease activity in SLE, and indicates that their expression was significantly elevated in patients with LN, suggesting they may serve as potential noninvasive indicators warranting further longitudinal investigation for LN risk assessment.

Abstract

Background Systemic lupus erythematosus (SLE) has multiple phenotypes, one of which is lupus nephritis (LN), a very serious complication with a high mortality rate. Patients with LN may require different treatment regimens than patients with SLE, as there are significant differences between SLE and LN pathogenesis; however, to date, no biomarkers specific for LN have been characterized. Identification of immunological markers of LN could therefore facilitate more individualized treatment strategies. Materials and Methods Using public datasets (GSE121239), we screened patients based on SELENA‐SLEDAI scores into mild (SLELA), moderate‐to‐severe (SLEHA), and healthy control (HC) groups. Bioinformatics analyses identified differentially expressed genes (DEGs), which were analyzed for functional pathway enrichment and immune cell infiltration. We validated these findings in an independent clinical cohort of 40 SLE patients (20 with LN and 20 without LN) and 20 HC individuals. LN diagnosis was confirmed by renal biopsy or clinical criteria. We assessed disease activity using clinical indicators and measured the expression of MX2, IRF7, and TRIM69 in peripheral blood mononuclear cells (PBMCs) via real‐time quantitative PCR (n = 40). Serum interferon‐α (IFN‐α) levels were measured by ELISA, and protein expression in kidney tissue was detected by immunofluorescence (IF). Results We observed differential expression of 32 disease activity‐related genes in SLE. Univariate logistic regression and ROC curve analysis indicated that MX2 (AUC = 0.95, 95% CI: 0.92–0.98), TRIM69 (AUC = 0.93, 95% CI: 0.89–0.96), and IRF7 (AUC = 0.91, 95% CI: 0.87–0.95) were associated with SLE diagnosis. Gene ontology functional enrichment analysis suggested that the type I IFN pathway is aberrantly activated in SLE. Disease activity‐related genes such as MX2, IRF7, and IFIT3 are functionally enriched in the type I IFN pathway, and abnormal infiltration of neutrophils is involved in SLE pathogenesis. Disease activity‐related genes such as MX2 and IRF7 were positively correlated with immune cell infiltration, including neutrophils and memory B cells. RT‐qPCR and ELISA showed significantly higher expression of IFN‐α, MX2, and IRF7 in LN patients than in SLE patients. IF assays showed that IFN‐α, MX2, and IRF7 were expressed at significantly higher levels in the kidneys of LN patients than in SLE patients. Conclusions Our study identifies MX2 and IRF7 as candidate biomarkers associated with high systemic disease activity in SLE. In our validation cohort, their expression was significantly elevated in patients with LN, suggesting they may serve as potential noninvasive indicators warranting further longitudinal investigation for LN risk assessment.

Read PDF

Similar papers

Review Open access Aug 2026

Targeting IFN signaling as therapeutic option for lupus nephritis.

The course of systemic lupus erythematosus (SLE) is highly heterogeneous, with clinical manifestations varying considerably among patients and multiple immune pathways implicated in disease progression. Regardless of this variability, lupus nephritis (LN) is a frequent organ manifestation of SLE and often progresses to...

M. Meineck, Janine Riepl, P. Claßen et al. · 0 citations
Open access Sep 2026

SDF4 is a potential biomarker for diagnosis and severity assessment in patients with systemic lupus erythematosus

The implementation of refined management of systemic lupus erythematosus (SLE) poses a considerable challenge in clinical practice. In this study, we evaluated serum stromal cell-derived factor 4 (SDF4) as potential biomarkers for SLE diagnosis, disease severity, and prognosis. We determined the SDF4 level...

Xi Chen, Xuan-Zhe Yang, Jing Chen et al. · 0 citations
Open access Oct 2026

Clinical utility of serum autotaxin in systemic lupus erythematosus: association with disease activity and renal involvement

Emerging evidence indicates that autotaxin (ATX) produced by plasmacytoid dendritic cells contributes to immune dysregulation and the pathogenesis of systemic lupus erythematosus (SLE). ATX is closely associated with type I interferon signaling, highlighting its potential role as a biomarker and key mediator of SLE. Th...

Zahraa I. Selim, Maha S. I. Abdelrahman, Mariam M. Abd-Elrazik et al. · 0 citations
Open access Sep 2026

IFNG rs2430561 polymorphism and its association with disease onset, cutaneous severity, and activity in Vietnamese patients with lupus erythematosus.

The IFNG rs2430561 A allele is associated with earlier onset and more severe cutaneous and systemic disease in Vietnamese LE patients, highlighting the potential contribution of IFN-γ pathway variation to disease expression.

Thi Xuan Tam Huynh, Thành Luân Phan · 0 citations
Open access Jul 2026

Unveiling the molecular and immune heterogeneity across distinct disease activity states of systemic lupus erythematosus through integrative bulk and single-cell transcriptomics

Abstract Objective Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterised by substantial variability in clinical presentations and disease severity. This study aims to investigate the molecular and cellular mechanisms underlying distinct SLE Disease Activity Index (SLEDAI)-defined disease stat...

Chen Shen, Ming-Zhe Guo, Jian Huang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.